Cover Image
市場調查報告書

全球類風濕性關節炎 (RA) 治療藥市場預測

Global Rheumatoid Arthritis Drug Market Outlook 2022

出版商 KuicK Research 商品編碼 452418
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球類風濕性關節炎 (RA) 治療藥市場預測 Global Rheumatoid Arthritis Drug Market Outlook 2022
出版日期: 2017年03月01日 內容資訊: 英文 90 Pages
簡介

本報告提供全球類風濕性關節炎 (RA) 治療藥市場相關調查分析,分類、分子機制,治療藥概要,全球市場,市場動態,未來預測,競爭情形等系統性資訊。

第1章 抗風濕藥:類風濕性關節炎 (RA)的發病

  • RA的徵兆
  • RA的治療方法

第2章 抗風濕藥的分子機制

  • RA中DMARDs的目的
  • RA中生物製藥所扮演的角色

第3章 RA治療藥的分類

  • 傳統的RA治療藥的分類
  • 新建議的DMARDs的分類

第4章 RA治療藥的合成DMARDs

  • Methotrexate (MTX)
  • Sulfasalazine (SSZ)
  • Leflunomide
  • Hydroxychloroquine (HCQ)

第5章 RA治療藥的生物製藥

  • 細胞激素抑制劑
  • 白細胞介素
  • T細胞、B細胞抑制劑

第6章 RA的全球患者數

  • 美國
  • 歐洲
  • 加拿大
  • 亞洲

第7章 抗風濕藥的使用上的全球趨勢

  • 從傳統到生物學的DMARDs
  • 全球抗風濕藥處方趨勢

第8章 RA治療藥的全球市場

  • DMARDs的市場概要
  • 生技仿製藥DMARDs的市場
  • 主要的DMARDs:各收益

第9章 全球RA治療藥市場:動態

  • 推動因素
  • 主要課題

第10章 全球RA治療藥市場:未來預測

第11章 競爭情形

  • Abbvie
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celgene
  • Celltrion
  • J&J
  • MedImmune
  • Merck
  • Novartis
  • 武田藥品工業
目錄

“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi & Otezla) have dominated the overall anti-rheumatics market with total revenue surpassing more than US$ 25 Billion in 2016. These drugs will remain strong over the next 5 years, despite expected biosimilar competition.

Therapeutic advances have transformed the rheumatoid arthritis treatment paradigm over the last 20 years, from focusing on symptom management to now aiming for slowed disease progression and even disease remission. Disease-modifying biological medicines have ushered in a new age of treatment by targeting the cells involved in the progression of the disease.

These medicines have dramatically slowed or even reversed the negative physical effects associated with the disease and made clinical remission possible for patients with severe rheumatoid arthritis. The market of anti-rheumatics is growing at a constant speed globally. There are some driving factors which are accelerating the growth of anti-rheumatics market such as the increasing number of patients with rheumatoid arthritis, rise in research and development activities, increasing awareness among people about rheumatoid arthritis, and improved healthcare infrastructure in the region.

Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the molecular mechanisms involved. That approach changed with the introduction of biologic therapeutics at the end of the 20th century and by the recent development of small-molecule inhibitors of intracellular signal transduction pathways.

TNF-blocking biologic agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s. Further biologic agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy. During the last few years, another wave of novel discoveries led to the development of a new class of small molecule anti-inflammatory compounds targeting intracellular signal transduction molecules, such as tyrosine kinases.

The most valuable development in treating Rheumatoid Arthritis will be biomarkers to help diagnose it early, identify those with more severe disease requiring more aggressive treatment, and indicate the most appropriate therapy for each person. Biomarkers may even help to decide the best time to step down therapy when a patient is in remission. There is a huge amount of research taking place, which reflects the excellent relationships between rheumatology health care professionals and people with Rheumatoid Arthritis.

“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights:

  • Classification & Molecular Mechanism of Rheumatoid Arthritis Drugs
  • Synthetic DMARDs as Rheumatoid Arthritis Drug
  • Biological Agents as Rheumatoid Arthritis Drug
  • Global Market of Rheumatoid Arthritis Drug
  • Global Tendencies in Use of Antirheumatics
  • Global Rheumatoid Arthritis Drug Market Future Prospect

Table of Contents

1. Antirheumatoids: Call of Rheumatoid Arthritis

  • 1.1. Prologue towards Rheumatoid Arthritis
  • 1.2. Obtainable Treatment for Rheumatoid Arthritis

2. Molecular Mechanism of Antirheumatoids

  • 2.1. Purpose of DMARDs in Rheumatoid Arthritis
  • 2.2. Role of Biological Agents in Rheumatoid Arthritis
    • 2.2.1. TNF- Inhibitors
    • 2.2.2. Interleukin -1 & IL-6 Blockers

3. Classification of Rheumatoid Arthritis Drugs

  • 3.1. Traditional Classification of Rheumatoid Arthritis Drugs
  • 3.2. New Proposed Classification of DMARDs

4. Synthetic DMARDs as Rheumatoid Arthritis Drug

  • 4.1. Methotrexate (MTX)
  • 4.2. Sulfasalazine (SSZ)
  • 4.3. Leflunomide
  • 4.4. Hydroxychloroquine (HCQ)

5. Biological Agents as Rheumatoid Arthritis Drug

  • 5.1. Cytokine Inhibitors
    • 5.1.1. Etanercept (Enbrel)
    • 5.1.2. Infliximab (Remicade)
    • 5.1.3. Adalimumab (Humira)
    • 5.1.4. Golimumab (Simponi)
    • 5.1.5. Certolizumab pegol (Cimzia)
  • 5.2. Interleukin 1 & Interleukin 6 Inhibitors
    • 5.2.1. Anakinra (Kineret)
    • 5.2.2. Tocilizumab (RoActerma)
  • 5.3. T-Cell & B-Cell Inhibitors
    • 5.3.1. Abatacept (Orencia)
    • 5.3.2. Rituximab (Mabthera)

6. Global Prevalence of Rheumatoid Arthritis

  • 6.1. US
  • 6.2. Europe
  • 6.3. Canada
  • 6.4. Asia

7. Global Tendencies in Use of Antirheumatics

  • 7.1. Trail from Conventional to Biological DMARDs
  • 7.2. Global Trends of Antirheumatic Prescription

8. Global Market of Rheumatoid Arthritis Drug

  • 8.1. Market Overview of DMARDs
  • 8.2. Market of Biosimilar DMARDs
  • 8.3. Top Leading DMARDs by Revenues (2015 & 2022)
    • 8.3.1. Humira (Adalimumab)
    • 8.3.2. Enbrel (Etanercept)
    • 8.3.3. Remicade
    • 8.3.4. Simponi
    • 8.3.5. Otezla (Celgene)

9. Global Rheumatoid Arthritis DrugMarket Dynamics

  • 9.1. Accelerative Parameters
  • 9.2. Challenges

10. Global Rheumatoid Arthritis Drug Market Future Prospect

11. Competitive Landscape

  • 11.1. Abbvie
  • 11.2. Biogen Idec
  • 11.3. Bristol-Myers Squibb
  • 11.4. Celgene
  • 11.5. Celltrion
  • 11.6. J&J
  • 11.7. MedImmune
  • 11.8. Merck
  • 11.9. Novartis
  • 11.10. Takeda

List of Figures

  • Figure 1-1: Representation of the Disease Progression in Rheumatoid Arthritis
  • Figure 2-1: Mechanism of Action of Anti-TNF in Rheumatoid Arthritis Treatment
  • Figure 3-1: Classified Antirheumatic Drugs Pattern in Course of Treatment
  • Figure 3-2: Demonstration of New Nomenclature for Antirheumatic Drugs
  • Figure 4-1: Structure of Several Synthetic Antirheumatic DMARDs
  • Figure 5-1: ACR Response Rate of Infliximab vs. Biosimilar CT-P13
  • Figure 5-2: Immunoglobulin Structures of the TNF Agonists including all Five Classes
  • Figure 6-1: Worldwide Prevalence of Rheumatoid Arthritis
  • Figure 6-2: Percentage of Rheumatoid Arthritis by Gender in US
  • Figure 6-3: Prevalence of Rheumatoid Arthritis over Ethnicity
  • Figure 6-4: Incidence of Rheumatoid Arthritis with Increasing Age
  • Figure 6-5: Illustration of Upcoming Risk of RA in US
  • Figure 6-6: Illustration of Percentage of Prevalence of Rheumatic Arthritis
  • Figure 6-7: Projected Number of Individuals with Rheumatism in Canada
  • Figure 7-1: Traditional Mode of Rheumatoid Arthritis Treatment
  • Figure 7-2: Illustration of Changes in Use of DMARDs after MTX
  • Figure 7-3: US: Percentage of Type of DMARDs Used for RA in 2013
  • Figure 8-1: Global - Rheumatoid Arthritis Drug Sales (US$ Billion), 2015-2022
  • Figure 8-2: Patent Expiration of Major Antirheumatic Drugs under Biologics in EU & US
  • Figure 8-3: Global - Top Rheumatoid Arthritis Drugs by Revenue from 2015 & 2022
  • Figure 8-4: Global - Share of Top Rheumatoid Arthritis Drugs in Market (%),2022
  • Figure 8-5: Global - Humira Sales (US$ Billion), 2011-2015 & 2022
  • Figure 8-6: Global - Enbrel Sales (US$ Billion), 2015- 2016 & 2022
  • Figure 8-7: Global - Remicade Sales (US$ Billion), 2015 & 2022
  • Figure 8-8: Global Percentage of Simponi Sale Revenues by Region (2015-2022) (Billions)
  • Figure 8-9: Global - Simponi Sales (US$ Billion), 2015 & 2022
  • Figure 8-10: Global - Otezela Sales (US$ Billion) 2015 & 2022
  • Figure 9-1: Major Driving Forces of Antirheumatics Drug Market
  • Figure 9-2: Increasing Market Size of Biosimilars Worldwide
  • Figure 9-3: Major Challenges faced by Antirheumatics Market
  • Figure 9-4: Average Annual Treatment Cost of Humira, Enbrel & Remicade (US$), 2014
  • Figure 10-1: Global - Rheumatoid Arthritis Drug Market by Drug Class (TNF Inhibitors, JAK Inhibitors & Others) 2022
Back to Top